[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-455679-105":59,"doc-detail-455679-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","correction-to-treating-hematological-malignancies-with-or-2100-an-orally-bioavailable-prodrug-of-decitabine","Correction to “Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of Decitabine”","","Correction notice for a Cancer Science article titled “Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of Decitabine.” The document fixes errors in Table 1 reference citations by providing the corrected table of OR-2100 efficacy and molecular mechanisms across multiple hematological malignancy models, and replaces the incorrect Figure 3 legend with the correct description including survival analysis and context. It also corrects a sentence in the section “2.3 OR21 Monotherapy in ATL” by updating the cited reference number for promoter hypermethylation findings. The notice includes an apology and states Creative Commons open-access terms with proper citation requirements.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/correction-to-treating-hematological-malignancies-with-or-2100-an-orally-bioavailable-prodrug-of-decitabine/455679/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/correction-to-treating-hematological-malignancies-with-or-2100-an-orally-bioavailable-prodrug-of-decitabine/455679.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-08","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was corrected in Table 1?","Question",{"text":112,"@type":113},"The reference citations in Table 1 were incorrect; the corrected table is provided with updated citations for disease models and treatment approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What change was made to the Figure 3 legend?",{"text":117,"@type":113},"The Figure 3 legend was incorrect and is replaced with the correct legend describing OR-2100’s prevention of leukemogenesis, AKR mouse tumor methylation comparisons, and Kaplan–Meier survival curves.",{"name":119,"@type":110,"acceptedAnswer":120},"Which specific text and reference was corrected in section “2.3 OR21 Monotherapy in ATL”?",{"text":121,"@type":113},"The cited reference number in a sentence about genes negatively regulating T-cell receptor signaling was corrected from [16] to [30].","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},455679,1790792867,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Cancer Science  \nCorrection to “Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of Decitabine”  \nWatanabe, T., Kidoguchi, K. and Kimura, S. (2025), Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of Decitabine. Cancer Sci, 116: 853–861. [https://doi.org/10.1111/cas.16452](https://doi.org/10.1111/cas.16452)  \nIn Table 1, the reference citations were incorrect. The correct table is shown below:  \nTABLE 1 | Efficacy and molecular mechanisms of OR-2100 in mouse models of hematological malignancies.  \n\n| Disease | Treatment | Molecular mechanisms (key molecules) | References |\n| --- | --- | --- | --- |\n| Colon cancer | Monotherapy |  | [14] |\n| MDS/AML | Monotherapy | Induction of differentiation-related genes | [28] |\n| ATL | Monotherapy | Induction of negative regulatorsofTCR signaling | [30] |\n| Lymphocytic leukemia | Monotherapy | Down-regulation of MYC expression | [48] |\n| MDS/AML | Combination therapy (venetoclax) | Induction of ROS, down-regulation of VAMP7 | [18] |\n| CML | Combination therapy (ABL TKI) | Induction of PTPN6 | [55] |\n| ALCL | Combination therapy (ALK TKI) | Down-regulation ofWnt/β-catenin pathway | [62] |\n| ATL | Combination therapy (EZH inhibitor) | Induction of DUSP5 | [21] |\n\nFigure 3 legend was incorrect. The correct legend is shown below:  \nFIGURE 3 OR-2100 prevents leukemogenesis associated with aberrant DNA methylation in AKR mice. Tumor cells isolated from AKR mice have hypermethylated proximal promoter regions compared with normal T cells (left panel) . Kaplan–Meier survival curves ofAKR mice treated with vehicle, OR-2100, or DAC (right panel) [48] . Part of material from: Yuta Yamamoto et al., DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis, Leukemia, 2024, Springer Nature.  \nIn the third paragraph of the section “2.3 OR21 Monotherapy in ATL,” the text “Several genes that negatively regulate T-cell receptor signaling, including THEMIS, LAIR1, andRNF130, were down-regulated through promoter hypermethylation in ATL cells [16] .” was incorrect.  \nThis should have read: “Several genes that negatively regulate T-cell receptor signaling, including THEMIS, LAIR1, and RNF130, were down-regulated through promoter hypermethylation in ATL cells [30] .”  \nWe apologize for these errors.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.  \nCancer Science, 2026; 117:281 281  \n[https://doi.org/10.1111/cas.70230](https://doi.org/10.1111/cas.70230)","cbCaivqzBwAVS9Yh","https://ap.wps.com/l/cbCaivqzBwAVS9Yh","pdf",100037,"English","# Correction details\n## Table 1 citation corrections\n## Figure 3 legend correction\n## Section 2.3 (OR21 Monotherapy in ATL) citation correction","[{\"question\":\"What was corrected in Table 1?\",\"answer\":\"The reference citations in Table 1 were incorrect; the corrected table is provided with updated citations for disease models and treatment approaches.\"},{\"question\":\"What change was made to the Figure 3 legend?\",\"answer\":\"The Figure 3 legend was incorrect and is replaced with the correct legend describing OR-2100’s prevention of leukemogenesis, AKR mouse tumor methylation comparisons, and Kaplan–Meier survival curves.\"},{\"question\":\"Which specific text and reference was corrected in section “2.3 OR21 Monotherapy in ATL”?\",\"answer\":\"The cited reference number in a sentence about genes negatively regulating T-cell receptor signaling was corrected from [16] to [30].\"}]","Correction to “Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of Decitabine” | PDF",1790743862]